Summary
The episode works through why features of the acute psychedelic experience can predict improvement without showing that they cause it, using published correlations from a small psilocybin trial to show how the timing of a measurement, such as a rating of the therapeutic alliance taken after dosing, can strengthen an association. Sarah and Kiffer consider how much the setting matters when dose is the strongest predictor of the acute response, and they appraise an invented methods paragraph using the 2025 reporting guidelines for setting. A hypothetical trial shows that the Bang blinding index can fail the stringent cut-off when participants guess from their own improvement, so a high index describes how well people guessed and leaves open what their guesses were based on. In a segment on challenging experiences, Sarah corrects a published benefit figure for a hypothetical response bias, and the hosts discuss how benefit and harm can occur in the same person. The hosts close by debating whether the subjective experience is necessary for therapeutic benefit.